Dossier
drug trial
Coverage of drug trial in the Nexus archive.
- Alzheimer's 'wonder drug' could delay disease for three years - 90% of brain damage vanished in new trial
A potential Alzheimer's drug may delay the disease for three years, with 90% of brain damage disappearing in a new trial. The results suggest significant therapeutic promise for treating Alzheimer's.
- Biogen stock sinks after Alzheimer's drug trial data fails to impress investors
Biogen's stock declined following the release of Alzheimer's drug trial data that failed to meet its primary goal. The study showed the drug's lowest dose outperformed higher doses in ways the company cannot yet explain.